SL
RAPP

Siren LLC’s Rapport Therapeutics RAPP Stock Holding History

Siren LLC’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7M Hold
641,469
– – 0.54% 47
2026
Q1 		$20.1M Sell
641,469
-67,000
-9% -$1.88M 0.56% 40
2025
Q4 		$21.5M Sell
708,469
-345,000
-33% -$9.55M 0.64% 39
2025
Q3 		$31.3M Buy
1,053,469
+675,000
+178% +$12M 1.22% 27
2025
Q2 		$4.3M Hold
378,469
– – 0.22% 68
2025
Q1 		$3.8M Sell
378,469
-5,728
-1% -$74.4K 0.21% 66
2024
Q4 		$6.82M Hold
384,197
– – 0.3% 60
2024
Q3 		$7.87M Buy
+384,197
New +$8.26M 0.39% 51

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Siren LLC's RAPP Position: Q2 2026 in Review

Siren LLC held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 641,469 shares worth $26.7M. The position accounts for 0.54% of the portfolio, ranked #47.

Siren LLC first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. The position peaked at $31.3M in Q3 2025. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Siren LLC held 641,469 shares of Rapport Therapeutics worth $26.7M as of Q2 2026.
  • Siren LLC left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up 0.54% of Siren LLC's portfolio in Q2 2026, its #47 holding.
  • Siren LLC first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Siren LLC's Rapport Therapeutics position peaked at $31.3M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.